Home Cart 0 Sign in  
X

[ CAS No. 939-70-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 939-70-8
Chemical Structure| 939-70-8
Chemical Structure| 939-70-8
Structure of 939-70-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 939-70-8 ]

Related Doc. of [ 939-70-8 ]

Alternatived Products of [ 939-70-8 ]

Product Details of [ 939-70-8 ]

CAS No. :939-70-8 MDL No. :MFCD00159994
Formula : C9H8N2O Boiling Point : -
Linear Structure Formula :- InChI Key :UYFMRVDIXXOWLR-UHFFFAOYSA-N
M.W : 160.17 Pubchem ID :70322
Synonyms :

Calculated chemistry of [ 939-70-8 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.11
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 46.29
TPSA : 45.75 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.38 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.49
Log Po/w (XLOGP3) : 1.27
Log Po/w (WLOGP) : 1.77
Log Po/w (MLOGP) : 0.67
Log Po/w (SILICOS-IT) : 2.32
Consensus Log Po/w : 1.5

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.12
Solubility : 1.21 mg/ml ; 0.00755 mol/l
Class : Soluble
Log S (Ali) : -1.83
Solubility : 2.37 mg/ml ; 0.0148 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.23
Solubility : 0.0932 mg/ml ; 0.000582 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.38

Safety of [ 939-70-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 939-70-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 939-70-8 ]
  • Downstream synthetic route of [ 939-70-8 ]

[ 939-70-8 ] Synthesis Path-Upstream   1~12

  • 1
  • [ 148-79-8 ]
  • [ 51-17-2 ]
  • [ 5805-52-7 ]
  • [ 939-70-8 ]
Reference: [1] Photochemical and Photobiological Sciences, 2014, vol. 13, # 2, p. 310 - 315
  • 2
  • [ 16414-04-3 ]
  • [ 939-70-8 ]
YieldReaction ConditionsOperation in experiment
85% With sodium hypochlorite; 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical; potassium bromide In water; acetonitrile at 10 - 15℃; for 0.5 h; To a solution of 1 (1.62 g, 0.01 mol), 2,2,6,6-tetramethylpiperidin(0.016 g, 0.1 mmol) and potassium bromide(0.12 g, 1 mmol) in 40 mL acetonitrile/water (1:1), 8percent aqueoussodium hypochlorite (13.96 g, 0.015 mol) was added over a 15–20 min period, keeping the temperature of the reaction mixturebetween 10 and 15 C. The mixture was stirred for 30 min andwas extracted with ethyl acetate (50 mL 3). The combinedextracts were washed with 60 mL of 10percent aqueous sodium thiosul-fate and 60 mL of saturated sodium chloride solution. The organicphase was separated, dried over anhydrous MgSO4 and evaporatedto afford compound 2 with 85percent yield, MS (ESI) m/z: 161 (M+H)+. 1HNMR (400 MHz, DMSO) d 13.31 (s, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.57(d, J = 8.1 Hz, 1H), 7.39 (t, J = 7.1 Hz, 1H), 7.31 (d, J = 7.2 Hz, 1H),2.72 (s, 3H).
70% With sulfuric acid; potassium dichromate In water at 20℃; for 0.333333 h; To a solution of 1-(1H-benzimidazol-2-yl)ethanol 1 (8.1 g,0.05 mol) in dilute sulphuric acid (40 ml), a solution ofpotassiumdichromate (9.8 g, 0.05 mol) in water (60 ml) wasadded at room temperature. To this mixture, concentratedsulphuric acid (20 ml) was added in a dropwise fashion,over a period of 20 min. The reaction mixture was stirredvigorously during addition. The separated solid was filteredand wash with water (30 ml). The precipitate obtained wasre-suspended in water (50 ml) and treated very carefullywith aqueous ammonia to obtain a pH 6.0–6.5. The suspensionwas stirred for 0.5 h and filtered. The residue 2 waswashed with water (3 × 10 ml) and dried. Yield = 70percent, m.p. 189–191 °C. IR (KBr) cm−1: 3358 (NH), 3024 (Ar-CH),2971 (CH3-CH), 1740 (C=O), 1647 (C=N), 1601 (C=C).1H-NMR (CDCl3, 500 MHz) δ ppm: 2.31 (s, 3H, CH3), 5.19(s, 1H, NH), 7.342–7.86 (m, 4H, Ar-CH). 13C-NMR(CDCl3, 500 MHz) δ ppm: 195.4 (C=O), 154.8 (C-2),140.5 (C-8 & C-9), 129.6 (C-5 & C-6), 117.2 (C-4 & C-7),29.7 (CH3). EI-MS m/z: 160 (M+). Anal. calcd forC9H8N2O: C, 67.49; H, 5.03; N, 17.49. Found: C, 67.68; H,5.04; N, 17.44.
69% at 80℃; The method for synthesizing 2-acetylbenzimidazole in this example is as follows:2-Hydroxyethylbenzimidazole (0.1 mol, 16.2 g)The ruthenium complex Ru(bpbp)(pydic) (10-4 mol, 0.0730 g) in Example 3 was added to the reaction vessel.Hydrogen peroxide (30percent, 0.3 mol, 9.1 ml) was slowly added to the reaction vessel with stirring.Control the reaction temperature below 80 °C for several hours.The reaction solution was concentrated under reduced pressure,Obtain a solid product,The solid product was dissolved in dichloromethane and subjected to silica gel column chromatography.Pure product 2-acetylbenzimidazole 11.0g was obtained. Yield 69percent.
64% With chromium(VI) oxide; acetic acid In water at 90 - 105℃; for 0.166667 h; A 50 mL round bottom flask was added 5.4 g (0.05 mol) of o-phenylenediamine,4.5 g (0.05 mol) of lactic acid and 20 ml of 4 mol / L hydrochloric acid,Heating reflux 1.5h,Cool to room temperature.With concentrated ammonia and purple purple litmus paper turned red,Filter out the solid,Recrystallization from water (63percent).To a 50 mL three-necked flask, 2.24 g (0.02 mol) of 2- (α-hydroxy) ethylbenzimidazole and 15 mL of glacial acetic acid were added,After heating to 90 ° C, an aqueous solution of CrO3 was added dropwise to the three-necked flask,After dripping,The reaction was stirred at 105 ° C for 10 min,The reaction was then poured into a beaker containing 200 mL of water,Stirring for a moment,Filter,The filtrate was extracted three times with chloroform,The chloroform layers were combined,Dried over anhydrous magnesium sulfate,The filtrate was evaporated to dryness to give a yellow solid,Recrystallization from toluene,Yield: 64percent.To a 50 mL three-necked flask was added 1.6 g of 2-acetylbenzimidazole, 15 mL of 2 mol / L NaOH solution, and 1.3 mL of bromoethane was added to the flask,After the dropwise addition, the three-necked flask was quickly placed in an ice bath and cooled to 0 ° C,5min after precipitation of a large number of solid,Filter,Washed,Dried to obtain a yellow solid,Yield: 79percentTo a 50 ml round bottom flask was added 20 ml of 95percent ethanol and 3.20 g (0.02 mol) of 1- (1-ethyl-1H-benzimidazol-2-ethyl)Stir for about 10 min to completely dissolve the solid,Further, 8 ml of a 10percent aqueous solution of sodium hydroxide was added,0.02 mol of 2-pyridinecarbaldehyde was added with stirring,After a period of time the system precipitates a lot of solid,The reaction end point was detected by TLC,After the reaction, the filtrate was filtered to obtain a solid, yield: 86percent
57% With Ru(2,6-bis(1-(phenyl)-1H-benzo[d]imidazol-2-yl)pyridine)(pbb)Cl; dihydrogen peroxide In water at 50℃; for 5 h; (1H-benzo[d]imidazol-2-yl)ethanol (0.1 mol, 14.8 g) and Ru(bpbp)(pbb)Cl(0.001mmol, 7.32 × 10−3 g) were added into a reactor. Thereactor containing this mixture was heated to 50 °C in an oilbath under vigorous stirring, and then 30percent H2O2 (30 mL,0.3mol) was slowly dropped into the reactor in 30min. Themixture was stirred for 5h. After filter, the solution wasevaporated under reduced pressure at 50 °C. After extractionwith CH2Cl2, the crude product was chromatographed onsilica gel (eluent: CH2Cl2). Pure 1-(1H-benzo[d]imidazol-2-yl)ethanone (0.07mmol, 10.2 g) was obtained with the isolated yield of 57percent by removing the solvent. The productwas identified by 1HNMR spectrum (400MHz, CDCl3)(Figure 5) and IR spectrum (Figure 6), which are all inagreement with the assumed structure. IR is also same withthe standard Bio-Rad/Sadtler IR Data.

Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2003, vol. 42, # 12, p. 3128 - 3130
[2] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 1, p. 8 - 16
[3] Dyes and Pigments, 2011, vol. 88, # 3, p. 344 - 349
[4] Chemical and Pharmaceutical Bulletin, 2010, vol. 58, # 7, p. 953 - 956
[5] Chemical and Pharmaceutical Bulletin, 2010, vol. 58, # 8, p. 1081 - 1084
[6] Chinese Chemical Letters, 2010, vol. 21, # 10, p. 1145 - 1148
[7] Journal of the Indian Chemical Society, 1999, vol. 76, # 3, p. 140 - 144
[8] Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, vol. 29, # 6, p. 811 - 822
[9] RSC Advances, 2017, vol. 7, # 26, p. 16253 - 16263
[10] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1993, vol. 32, # 10, p. 1035 - 1044
[11] Medicinal Chemistry Research, 2017, vol. 26, # 12, p. 3158 - 3172
[12] Patent: CN107445998, 2017, A, . Location in patent: Paragraph 0032-0035
[13] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2003, vol. 42, # 7, p. 1765 - 1767
[14] Canadian Journal of Chemistry, 2003, vol. 81, # 6, p. 612 - 619
[15] Patent: CN104140415, 2017, B, . Location in patent: Paragraph 0074; 0284
[16] Journal of Chemistry, 2017, vol. 2017,
[17] Journal of the Indian Chemical Society, 2002, vol. 79, # 12, p. 966 - 967
[18] Magnetic Resonance in Chemistry, 1987, vol. 25, p. 16 - 20
[19] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1999, vol. 38, # 3, p. 302 - 307
[20] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2003, vol. 42, # 2, p. 421 - 424
[21] Patent: US2006/94588, 2006, A1,
[22] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 5, p. 1573 - 1576
[23] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2008, vol. 47, # 7, p. 1096 - 1107
[24] European Journal of Medicinal Chemistry, 2010, vol. 45, # 1, p. 114 - 119
[25] Synthetic Communications, 2010, vol. 40, # 3, p. 414 - 422
[26] Chinese Journal of Chemistry, 2011, vol. 29, # 3, p. 539 - 543
[27] Letters in Drug Design and Discovery, 2011, vol. 8, # 4, p. 317 - 320
[28] Asian Journal of Chemistry, 2013, vol. 25, # 4, p. 1853 - 1856
[29] Heterocycles, 2013, vol. 87, # 5, p. 1121 - 1126
[30] Chemistry of Heterocyclic Compounds, 2015, vol. 51, # 1, p. 44 - 50[31] Khim. Geterotsikl. Soedin., 2015, vol. 51, # 1, p. 44 - 50,7
[32] European Journal of Medicinal Chemistry, 2016, vol. 114, p. 328 - 336
[33] Patent: CN106349235, 2017, A, . Location in patent: Paragraph 0010
[34] Journal of the Serbian Chemical Society, 2017, vol. 82, # 9, p. 985 - 993
[35] European Journal of Medicinal Chemistry, 2018, vol. 143, p. 66 - 84
[36] Patent: CN107759532, 2018, A, . Location in patent: Paragraph 0168; 0169
[37] Applied Organometallic Chemistry, 2018, vol. 32, # 11,
  • 3
  • [ 75-16-1 ]
  • [ 939-70-8 ]
YieldReaction ConditionsOperation in experiment
60% at 0 - 20℃; for 2.25 h; Inert atmosphere To a stirred solution of compound 190 (15 g, 73.13 mmol) in anhydrous THF (200 mL) under inert atmosphere was added methyl magnesium bromide (48.75 mL, 146.3 mmol, 3 M sol. in diethyl ether) dropwise for 15 min at 0 oC. The reaction mixture was stirred at 0 oC for 2 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate The combined organic extracts were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford compound 191 (7g, 60percent) as a yellow solid. TLC: 30percent EtOAc/ hexanes (Rf: 0.5); 1H NMR (400 MHz, DMSO-d6): δ δ 13.28 (s, 1H), 7.82-7.80 (m, 1H), 7.55-7.53 (m, 1H), 7.35-7.30 (m, 2H), 2.69 (s, 3H); LCMS Calculated for C9H8N2O: 160.06; Observed: 160.95 (M+1)+.
Reference: [1] Patent: WO2018/160878, 2018, A1, . Location in patent: Page/Page column 351-352
  • 4
  • [ 1848-84-6 ]
  • [ 939-70-8 ]
Reference: [1] Chemical Science, 2017, vol. 8, # 2, p. 1282 - 1287
[2] Chemistry - A European Journal, 2018, vol. 24, # 40, p. 10260 - 10265
  • 5
  • [ 10326-41-7 ]
  • [ 95-54-5 ]
  • [ 939-70-8 ]
YieldReaction ConditionsOperation in experiment
39% With manganese dioxide In hydrogenchloride; CH2Cl2/MeOH Preparation of 1-(1H-Benzimidazol-2-yl)-ethanone:
A solution of 1,2-phenylene diamine (3.25 g, 0.030 mol) and L-lactic acid (2.3 mL, 0.026 mol) in 3 M HCl (15 mL) was refluxed overnight.
The reaction was cooled to room temperature, diluted with EtOAc (50 mL) and saturated aqueous Na2CO3 and solid Na2CO3 to pH 10.
The aqueous phase was washed with EtOAc (1*50 mL) and the combined organic extracts dried (Na2SO4) and concentrated to afford a brown-orange solid which was used in the next reaction without further purification.
To a stirred solution of the crude alcohol from above (0.026 mol) in dry CH2Cl2/MeOH (6:1, 35 mL) was added activated manganese dioxide (85percent purity, <5 micron, 23.28 g, 0.228 mol) and the suspension stirred overnight, at which point the black slurry was filtered through a cake of celite and washed with MeOH (3*50 mL).
The combined washings were concentrated to afford a dark brown solid.
Purification of the crude product by column chromatography on silica gel (CH2Cl2MeOH, 98:2 to 95:5) afforded the title compound as a red-brown solid (1.65 g, 39percent).
1H NMR (CD3OD) δ 2.72 (s, 3H), 7.37 (dd, 2H, J=6, 3 Hz), 7.66-7.73 (br m, 2H).
Reference: [1] Patent: US2004/19058, 2004, A1,
  • 6
  • [ 860469-26-7 ]
  • [ 141-78-6 ]
  • [ 939-70-8 ]
Reference: [1] Tetrahedron Letters, 2005, vol. 46, # 30, p. 5081 - 5084
  • 7
  • [ 95-54-5 ]
  • [ 939-70-8 ]
Reference: [1] Dyes and Pigments, 2011, vol. 88, # 3, p. 344 - 349
[2] Chinese Chemical Letters, 2010, vol. 21, # 10, p. 1145 - 1148
[3] Letters in Drug Design and Discovery, 2011, vol. 8, # 4, p. 317 - 320
[4] Asian Journal of Chemistry, 2013, vol. 25, # 4, p. 1853 - 1856
[5] Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, vol. 29, # 6, p. 811 - 822
[6] Chemistry of Heterocyclic Compounds, 2015, vol. 51, # 1, p. 44 - 50[7] Khim. Geterotsikl. Soedin., 2015, vol. 51, # 1, p. 44 - 50,7
[8] European Journal of Medicinal Chemistry, 2016, vol. 114, p. 328 - 336
[9] Journal of Molecular Structure, 2017, vol. 1130, p. 463 - 471
[10] Patent: CN106349235, 2017, A,
[11] RSC Advances, 2017, vol. 7, # 26, p. 16253 - 16263
[12] Patent: CN104140415, 2017, B,
[13] Journal of the Serbian Chemical Society, 2017, vol. 82, # 9, p. 985 - 993
[14] Medicinal Chemistry Research, 2017, vol. 26, # 12, p. 3158 - 3172
[15] European Journal of Medicinal Chemistry, 2018, vol. 143, p. 66 - 84
[16] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 1, p. 8 - 16
[17] Patent: CN107759532, 2018, A,
[18] Applied Organometallic Chemistry, 2018, vol. 32, # 11,
  • 8
  • [ 192316-22-6 ]
  • [ 939-70-8 ]
Reference: [1] Journal of Molecular Structure, 2017, vol. 1130, p. 463 - 471
  • 9
  • [ 51-17-2 ]
  • [ 939-70-8 ]
Reference: [1] Tetrahedron Letters, 2005, vol. 46, # 30, p. 5081 - 5084
  • 10
  • [ 2849-93-6 ]
  • [ 939-70-8 ]
Reference: [1] Patent: WO2018/160878, 2018, A1,
  • 11
  • [ 127-17-3 ]
  • [ 95-54-5 ]
  • [ 939-70-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 9, p. 1621 - 1628
  • 12
  • [ 148-79-8 ]
  • [ 51-17-2 ]
  • [ 5805-52-7 ]
  • [ 939-70-8 ]
Reference: [1] Photochemical and Photobiological Sciences, 2014, vol. 13, # 2, p. 310 - 315
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 939-70-8 ]

Ketones

Chemical Structure| 29096-60-4

[ 29096-60-4 ]

1-(2-Methylimidazo[1,2-a]pyridin-3-yl)ethanone

Similarity: 0.60

Chemical Structure| 13220-57-0

[ 13220-57-0 ]

Indolo[2,1-b]quinazoline-6,12-dione

Similarity: 0.60

Chemical Structure| 85692-37-1

[ 85692-37-1 ]

1-(1-Methyl-1H-imidazol-2-yl)ethanone

Similarity: 0.58

Chemical Structure| 29096-64-8

[ 29096-64-8 ]

1-(Imidazo[1,2-a]pyridin-3-yl)ethanone

Similarity: 0.56

Chemical Structure| 53342-27-1

[ 53342-27-1 ]

1-(2-Pyrimidinyl)ethanone

Similarity: 0.54

Related Parent Nucleus of
[ 939-70-8 ]

Benzimidazoles

Chemical Structure| 3314-30-5

[ 3314-30-5 ]

1H-Benzo[d]imidazole-2-carbaldehyde

Similarity: 0.89

Chemical Structure| 1848-84-6

[ 1848-84-6 ]

2-Ethyl-1H-benzo[d]imidazole

Similarity: 0.84

Chemical Structure| 3012-80-4

[ 3012-80-4 ]

1-Methyl-1H-benzo[d]imidazole-2-carbaldehyde

Similarity: 0.84

Chemical Structure| 29518-68-1

[ 29518-68-1 ]

2-(1H-Benzo[d]imidazol-2-yl)ethanamine

Similarity: 0.82

Chemical Structure| 88704-72-7

[ 88704-72-7 ]

2-(1H-Benzo[d]imidazol-2-yl)ethanamine hydrochloride

Similarity: 0.81